Early Trial Points to T-Cell Therapy’s Potential Against Treatment-Resistant Cancers

Early findings from the first human clinical trial of a precision T-cell therapy suggest it may help control cancers that have resisted most other treatments.

The initial results point to the treatment’s potential to halt disease progression, offering a possible new approach for patients whose cancers have proved difficult to manage.

The cancers described include those that did not respond to immunotherapy. That makes the early findings relevant to cases in which previous attempts to harness the immune system against cancer have been unsuccessful.

The results remain preliminary, however, and do not establish the therapy as a proven treatment. Further clinical evidence will be needed to determine its effectiveness, safety and how long any control of the disease may last.